Lease

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, December 5, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Employment, KALV, Pharmaceutical industry, Lease

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on December 1, 2023 as inducements material to each employee entering into employment with KalVista.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on December 1, 2023 as inducements material to each employee entering into employment with KalVista.
  • The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options have an exercise price of $8.82 per share, which was equal to the closing price of KalVista common stock on the grant date.
  • Each stock option has a 10-year term and is subject to the terms and conditions of KalVista’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, December 4, 2023
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Employment, Allergy, Therapy, Pharmaceutical industry, Lease

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 52,000 shares of Astria’s common stock on December 1, 2023 under Astria’s 2022 Inducement Stock Incentive Plan.

Key Points: 
  • Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 52,000 shares of Astria’s common stock on December 1, 2023 under Astria’s 2022 Inducement Stock Incentive Plan.
  • The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.
  • The options were granted as an inducement material to two employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the grant.

Cool Company Ltd.: Granting Of Share Options And Restricted Stock Units To Primary Insiders and Mandatory Notification of Trades

Retrieved on: 
Friday, December 1, 2023
Oil, Gas, Energy, Other Transport, Supply Chain Management, Maritime, Logistics, Transport, Retail, RSU, CFO, Multimedia, Option, USD, Press release, LTIP, Cryptocurrency, Lease

The Company anticipates that the shares underlying the vested RSUs will be issued to grantees on or after December 7, 2023.

Key Points: 
  • The Company anticipates that the shares underlying the vested RSUs will be issued to grantees on or after December 7, 2023.
  • Additionally, the Company’s board of directors (the “Board”) has resolved, in accordance with the LTIP, to authorize options (“Options”) and RSUs for 2023, as further detailed below.
  • Richard Tyrrell, CEO and Director of the Company, has on December 1, 2023 acquired 2,030 shares in the Company at a price of USD 12.49 per share.
  • The following Primary Insiders have been granted Options and RSUs, and purchased shares as per the below:
    Sami Iskander (Director) has been granted 37,123 Options.

MedMen Provides Annual Filing Status Report

Retrieved on: 
Thursday, November 30, 2023
Alternative Medicine, Cannabis, Retail, Health, Other Retail, Natural Resources, Specialty, British Columbia Securities Commission, CSE, CFO, National Policy, Bank statement, Corporation, Initial, Franchise disclosure document, Managed file transfer, Lease

MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a premier cannabis company with operations across the United States, is providing this bi-weekly default status report in accordance with National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

Key Points: 
  • MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a premier cannabis company with operations across the United States, is providing this bi-weekly default status report in accordance with National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
  • The Company anticipates that the Required Filings will be completed on or before December 13, 2023.
  • The Company has not taken any steps towards any insolvency proceeding and the Company has no material information to release to the public.
  • The Company has made the foregoing representations in accordance with the requirements of applicable securities laws.

Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, November 28, 2023
Other Health, Research, General Health, Pharmaceutical, Oncology, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, Other Science, Health, Common stock, Precision BioSciences, Employment, Gene editing, Compensated emancipation, Precision, Pharmaceutical industry, Lease

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award to a new employee under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan”).

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award to a new employee under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan (“Inducement Award Plan”).
  • The inducement award consists of an option to purchase (“stock option”) 160,000 shares of Precision’s common stock, par value $0.000005 (the “Common Stock”), which was granted to an employee in connection with their commencement of employment.
  • The stock option was granted under Nasdaq Listing Rule 5635(c)(4) as an inducement for the employee to commence service with Precision.
  • The stock option has a per share exercise price equal to the fair market value of Precision’s Common Stock on the grant date, which was equal to $0.42.

Citigroup Center in Downtown Miami Announces 38,000 SF of New Leasing Activity

Retrieved on: 
Tuesday, November 28, 2023
Commercial Building & Real Estate, Construction & Property, Other Retail, Urban Planning, REIT, Interior Design, Building Systems, Other Construction & Property, Retail, Residential Building & Real Estate, Lithium, MIA, City, MacArthur Causeway, Cactus Club Cafe, Miami International Airport, Multimedia, WELL, Heart, Citigroup, Marex, Intercontinental, Health, Tenant, Citigroup Center, Starbucks, ATM, DDA, Brickell Avenue, Growth, Bayfront Park, Bayfront Park station, JLL, Self storage, Lease, Commercial property, Property management, Drug, Hotel, Brickell, Biscayne Bay

Citigroup Center , an 810,000-square-foot, 34-story trophy tower in Downtown Miami and the second-largest Class A office building in Florida, today announced that it has executed 38,731 total square feet of leasing agreements.

Key Points: 
  • Citigroup Center , an 810,000-square-foot, 34-story trophy tower in Downtown Miami and the second-largest Class A office building in Florida, today announced that it has executed 38,731 total square feet of leasing agreements.
  • Four of the new tenants will occupy brand new spec suites completed by Citigroup Center.
  • Lithium Capital Management, a Chile-based investment advisory firm, signed a lease for a new 2,443-square-foot spec suite as the location for its Miami office.
  • Miami Downtown Development Authority (DDA), an independent agency of the City of Miami, signed a lease for a 9,295-square-foot office space for its relocation from its existing office location in Downtown Miami.

Nighthawk and Moneta Announce At-Market Merger to Create a Leading Canadian Gold Development Company

Retrieved on: 
Tuesday, November 28, 2023
Mining, Minerals, Natural Resources, Sale, Economics, Engineering, Interim, Toronto Stock Exchange, Feasibility study, Project, Tower, Sky (New Zealand), Arrangement, Name, Senior Officer Present Afloat, TSX, News, Model Business Corporation Act, NHK, ESG, Transaction, OTCQX, MOPA, Gold, Multimedia, G&A, Qualified person (European Union), Underwriting, Person, Cobham Technical Services, Feasibility, IRR, FSE, Geology, Par value, Prospectus, Consolidation, LLP, Warrant, Inference, Nature, Name change, Master of Science, Concurrency, Regulation, Security (finance), Bank, Management, Renewable energy, Risk management, Financial adviser, Audit, Lease, Holding company, Commercial property

Keyvan Salehi, President, CEO and Director of Nighthawk, and Josef Vejvoda, Interim CEO & Chairman of Moneta, jointly commented: “We believe that the Transaction presents an exciting opportunity to create a leading gold development company by bringing together two cornerstone assets in Canada.

Key Points: 
  • Keyvan Salehi, President, CEO and Director of Nighthawk, and Josef Vejvoda, Interim CEO & Chairman of Moneta, jointly commented: “We believe that the Transaction presents an exciting opportunity to create a leading gold development company by bringing together two cornerstone assets in Canada.
  • MergeCo will be underpinned by a considerable mineral resource of 7.8 million gold ounces in the Indicated category and 10.0 million gold ounces in the Inferred category1.
  • Potential to utilize excess mill capacity in proximity to the Tower Gold Project and accelerate towards near-term cash flow.
  • Synergies – Potential to unlock both G&A and operational efficiencies with seasonal workflow sequencing, staggered and phased development of the Projects.

Immunology Collaboration and Licensing Agreements Analysis Report 2023 with Directory of Deals Signed Since 2016 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 23, 2023
Biotechnology, Pharmaceutical, Health, Confidentiality, Chapter Six, Chapter, Intellectual property, Directory, Chapter Five, A-Z, Chapter Four, Hyperlink, Orientation, Chapter Three, Chapter One, Vaccine, Pharmaceutical industry, Cryptocurrency, Publishing, Risk management, Property management, Commercial property, Lease

Immunology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the worlds leading biopharma companies.

Key Points: 
  • Immunology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the worlds leading biopharma companies.
  • Fully revised and updated, the report provides details of immunology deals from 2016 to 2023.
  • The report also includes numerous table and figures that illustrate the trends and activities in immunology deal making since 2016.
  • Chapter 5 provides a comprehensive and detailed review of immunology deals signed and announced since 2016 where a contract document is available.

Global Hospital Care Collaboration and Licensing Agreements Analysis Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 23, 2023
Health, Hospitals, Confidentiality, Chapter Six, Chapter, Intellectual property, Directory, Chapter Five, A-Z, Chapter Four, Hyperlink, Orientation, Chapter Three, Chapter One, Nursing, Cryptocurrency, Publishing, Risk management, Property management, Commercial property, Lease

Fully revised and updated, the report provides details of hospital care deals from 2016 to 2023.

Key Points: 
  • Fully revised and updated, the report provides details of hospital care deals from 2016 to 2023.
  • Hospital Care Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hospital care deals entered into by the worlds leading biopharma companies.
  • The report also includes numerous table and figures that illustrate the trends and activities in hospital care deal making since 2016.
  • Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in hospital care dealmaking.

Dermatology Collaboration and Licensing Deals Analysis Report and Directory 2016-2023 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 23, 2023
Biotechnology, Pharmaceutical, Health, Confidentiality, Chapter Six, Chapter, Intellectual property, Directory, Chapter Five, A-Z, Chapter Four, Hyperlink, Dermatology, Orientation, Chapter Three, Chapter One, Veterinary medicine, Commercial property, Cryptocurrency, Publishing, Risk management, Property management, Lease

The "Dermatology Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dermatology Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.
  • Fully revised and updated, the report provides details of dermatology deals from 2016 to 2023.
  • Dermatology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the dermatology deals entered into by the worlds leading biopharma companies.
  • Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in dermatology dealmaking.